Kim Y I, Giuliano A, Hatch K D, Schneider A, Nour M A, Dallal G E, Selhub J, Mason J B
Vitamin Bioavailability Laboratory, USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111.
Cancer. 1994 Aug 1;74(3):893-9. doi: 10.1002/1097-0142(19940801)74:3<893::aid-cncr2820740316>3.0.co;2-b.
Global DNA hypomethylation has been observed in some human neoplasms and has been implicated as an important factor in carcinogenesis. The current study was designed to assess whether DNA hypomethylation occurs in cervical dysplasia and cancer, and to determine the relationship between the degree of DNA hypomethylation and the grade of neoplasia.
Cervical biopsy specimens were obtained from colposcopically identifiable lesions in 41 patients with abnormal Pap smear results. The extent of global DNA methylation was assessed by incubating the extracted DNA with [3H]-S-adenosylmethionine and Sss1 methyltransferase, an enzyme that specifically catalyzes the transfer of methyl groups to cytosine residues in the cytosine-guanine doublet. The degree of exogenous 3H-methyl group incorporation into the DNA therefore is related reciprocally to the extent of endogenous DNA methylation. These data were compared with the histopathologic classification of the lesions.
The extent of 3H-methyl group incorporation was increased threefold and sevenfold in the DNA from cervical dysplasia and cancer, respectively, compared with the DNA from normal cervical tissue (P = 0.006, analysis of variance). Significant incremental increases in DNA hypomethylation were observed in the progression from normal and low grade squamous intraepithelial lesions (SIL) to high grade SIL and to cancer (P < 0.0001, trend).
These data show that global DNA hypomethylation is a significant epigenetic event in cervical carcinogenesis and that the degree of DNA hypomethylation increases with the grade of cervical neoplasia. These data suggest that global DNA methylation may serve as a biochemical marker of cervical neoplasia.
在一些人类肿瘤中已观察到全基因组DNA低甲基化,并且其被认为是致癌过程中的一个重要因素。本研究旨在评估DNA低甲基化是否发生于宫颈发育异常和癌症中,并确定DNA低甲基化程度与肿瘤分级之间的关系。
从41例巴氏涂片结果异常患者的经阴道镜可识别病变处获取宫颈活检标本。通过将提取的DNA与[3H]-S-腺苷甲硫氨酸和Sss1甲基转移酶(一种特异性催化甲基基团转移至胞嘧啶-鸟嘌呤双联体中胞嘧啶残基的酶)一起孵育来评估全基因组DNA甲基化程度。因此,外源性3H-甲基基团掺入DNA的程度与内源性DNA甲基化程度呈反比关系。将这些数据与病变的组织病理学分类进行比较。
与正常宫颈组织的DNA相比,宫颈发育异常和癌症的DNA中3H-甲基基团掺入程度分别增加了三倍和七倍(方差分析,P = 0.006)。在从正常和低级别鳞状上皮内病变(SIL)进展至高级别SIL和癌症的过程中,观察到DNA低甲基化有显著的逐步增加(趋势分析,P < 0.0001)。
这些数据表明,全基因组DNA低甲基化是宫颈致癌过程中一个重要的表观遗传事件,并且DNA低甲基化程度随宫颈肿瘤分级增加而升高。这些数据提示,全基因组DNA甲基化可能作为宫颈肿瘤的一个生化标志物。